Remepy, a biotechnology company developing a new class of medicines that combine prescription drugs with personalized, AI-driven therapeutic applications, has raised $36 million in a Series A financing round to expand its Hybrid Drug platform and advance its lead Parkinson’s disease program.
The financing was led by O.G. Venture Partners and M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany. Existing and new investors participating in the round include NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp. The latest financing brings Remepy’s total capital raised to $62 million.
Remepy said the proceeds will be used to accelerate pharmaceutical co-development partnerships, expand its Hybrid Drug pipeline and platform, and support global Phase III clinical development of Hybridopa, its lead investigational program for Parkinson’s disease. The company expects Phase III development to begin in the fourth quarter of 2026.
Hybrid Drugs are designed to combine conventional pharmacological treatments with personalized digital interventions. Remepy’s platform integrates prescription medicines with adaptive physical, cognitive, and behavioral interventions delivered through AI-driven therapeutic applications. The company believes this approach could enable multidisciplinary care through the existing prescription model while providing pharmaceutical companies with additional opportunities to improve treatment outcomes and differentiate their products.
The Hybrid Drug model could also offer strategic benefits to pharmaceutical companies, according to Remepy. These include opportunities to generate additional intellectual property, extend the lifecycle of existing medicines, differentiate current and future therapies, and potentially improve clinical trial outcomes through personalized and integrative treatment approaches.
The company’s strategy comes as regulatory frameworks for drug-software combination products continue to develop. Remepy said increasing regulatory alignment and emerging frameworks from the U.S. Food and Drug Administration are contributing to growing industry interest in combining pharmaceutical products with software-based interventions.
Remepy has also been expanding its relationships with pharmaceutical companies. The company recently announced a strategic collaboration with Merck KGaA to develop Hybrid Drugs across multiple therapeutic areas, beginning with rare tumors. The partnership represents a significant validation of Remepy’s approach and provides a pathway for applying its technology beyond its Parkinson’s disease program.
Hybridopa is currently the company’s most advanced Hybrid Drug program. The investigational treatment has produced encouraging results in a Phase IIa clinical study, with Remepy reporting improvements in both motor and non-motor symptoms associated with Parkinson’s disease. The company has also pointed to peer-reviewed publications examining the biological mechanisms that may underpin the clinical effects observed with its Hybrid Drug approach.
With the new financing, Remepy plans to prepare Hybridopa for global Phase III development, which is expected to begin in Q4 2026. The company emphasized that Hybridopa remains investigational and has not yet received approval from the FDA.
Michal Tsur, PhD, and Or Shoval, Co-CEOs of Remepy, said the financing would enable the company to move Hybridopa into Phase III while expanding its Hybrid Drug model across additional therapeutic areas. They described the company’s broader vision as combining breakthrough medicines with personalized intelligence to maximize their impact for individual patients.
Investors also highlighted the convergence of biotechnology, artificial intelligence, and digital health as a key factor behind their support for Remepy. O.G. Venture Partners said the company’s clinical data, regulatory progress, and pharmaceutical partnerships position Hybrid Drugs as a potentially important new approach to medicine development and delivery.
M Ventures similarly said Remepy’s model demonstrates the growing potential for AI to become integrated into the delivery of pharmaceutical and physical healthcare. The firm expects the technology to have applications across multiple drug classes and disease areas.
NFX, which has supported Remepy since its early stages, also participated in the financing. The firm said Remepy’s progress from an early-stage concept toward clinical and commercial development has strengthened its confidence in the company’s approach.
The Series A financing provides Remepy with additional resources to pursue its immediate clinical milestone while continuing to build a broader pipeline of Hybrid Drugs. If Hybridopa successfully advances through Phase III, the program could provide an important clinical validation of Remepy’s strategy to combine established pharmacology with personalized AI-driven interventions.